Titre :

Idecabtagene vicleucel in relapsed and refractory multiple myeloma

Auteur(s) :

Munshi, Nikhil C. [Auteur]
Anderson, Larry D. [Auteur]
Shah, Nina [Auteur]
Madduri, Deepu [Auteur]
Berdeja, Jesus [Auteur]
Lonial, Sagar [Auteur]
Raje, Noopur [Auteur]
Lin, Yi [Auteur]
Siegel, David [Auteur]
Oriol, Albert [Auteur]
Moreau, Philippe [Auteur]
Yakoub-Agha, Ibrahim [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Delforge, Michel [Auteur]
Cavo, Michele [Auteur]
Einsele, Hermann [Auteur]
Goldschmidt, Hartmut [Auteur]
Weisel, Katja [Auteur]
Rambaldi, Alessandro [Auteur]
Reece, Donna [Auteur]
Petrocca, Fabio [Auteur]
Massaro, Monica [Auteur]
Connarn, Jamie N. [Auteur]
Kaiser, Shari [Auteur]
Patel, Payal [Auteur]
Huang, Liping [Auteur]
Campbell, Timothy B. [Auteur]
Hege, Kristen [Auteur]
San-Miguel, Jesus [Auteur]

Titre de la revue :

The New England journal of medicine

Nom court de la revue :

N Engl J Med

Numéro :

384

Pagination :

705-716

Date de publication :

2021-02-25

ISSN :

1533-4406

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Idecabtagene vicleucel (ide-cel, also called bb2121), a B-cell maturation antigen-directed chimeric antigen receptor (CAR) T-cell therapy, has shown clinical activity with expected CAR T-cell toxic effects in patients with ...
Lire la suite >Idecabtagene vicleucel (ide-cel, also called bb2121), a B-cell maturation antigen-directed chimeric antigen receptor (CAR) T-cell therapy, has shown clinical activity with expected CAR T-cell toxic effects in patients with relapsed and refractory multiple myeloma. In this phase 2 study, we sought to confirm the efficacy and safety of ide-cel in patients with relapsed and refractory myeloma. Patients with disease after at least three previous regimens including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody were enrolled. Patients received ide-cel target doses of 150 × 1066 Of 140 patients enrolled, 128 received ide-cel. At a median follow-up of 13.3 months, 94 of 128 patients (73%) had a response, and 42 of 128 (33%) had a complete response or better. Minimal residual disease (MRD)-negative status (<10-5 Ide-cel induced responses in a majority of heavily pretreated patients with refractory and relapsed myeloma; MRD-negative status was achieved in 26% of treated patients. Almost all patients had grade 3 or 4 toxic effects, most commonly hematologic toxic effects and cytokine release syndrome. (Funded by bluebird bio and Celgene, a Bristol-Myers Squibb company; KarMMa ClinicalTrials.gov number, NCT03361748.).Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

CHU Lille
Inserm
Université de Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Date de dépôt :

2021-07-06T12:46:34Z
2024-02-01T13:21:22Z